TNFRSF11A and non-small cell lung carcinoma: BTAs, including bisphosphonates and denosumab, which were developed for the treatment of osteoporosis, have also been used to treat patients with NSCLC with bone metastases based on the association of the RANKL/RANK/NF-κB pathway with tumorigenesis.